Ansa Biotechnologies closed a $71.5 million Series C to expand its DNA manufacturing service, which waives fees when qualifying orders ship late. Blue Water Life Science Advisors led the round, the company announced November 18.
Ansa uses enzymes to manufacture researchers’ chosen DNA sequences, including constructs up to 50,000 base pairs, for experiments in drug discovery and gene editing. The company says its manufacturing capacity has quadrupled over the past year.
The Series C exceeds the $54.4 million Series B package announced in October 2025, which combined $45.2 million closed with $9.2 million in commitments.
Ansa has also widened access through Integrated DNA Technologies, a Danaher business. In a September 1 announcement, the companies said more than 400 institutions in 33 countries had ordered Ansa DNA through IDT since their collaboration began in January. Their expanded ordering system lets researchers compare synthesis options, prices and expected turnaround before buying.
The shipping guarantee applies only to qualifying purchases made directly from Ansa, according to its FAQ; partner orders and sequences it labels “Let’s Try” are excluded. Its terms allow large orders to carry separate shipping deadlines, with a fee waiver for the affected shipment if Ansa misses a covered deadline.